Clinical trial NCT04797338 - References

Miscarriage — Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders

Citation(s)

•   Atkinson P, Koch J, Ledger WL
  GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: a retrospective study of OHSS risk and pregnancy rates. Aust N Z J Obstet Gynaecol. 2014 Dec;54(6):581-5. doi: 10.1111/ajo.12277.
•   Balasch J, Martinez F, Jové I, Cabré L, Coroleu B, Barri PN, Vanrell JA
  Inadvertent gonadotrophin-releasing hormone agonist (GnRHa) administration in the luteal phase may improve fecundity in in-vitro fertilization patients. Hum Reprod. 1993 Jul;8(7):1148-51.
•   Bar-Hava I, Mizrachi Y, Karfunkel-Doron D, Omer Y, Sheena L, Carmon N, Ben-David G
  Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders. Fertil Steril. 2016 Aug;106(2):330-3. doi: 10.1016/j.fertnstert.2016.04.004. Epub 2016 Apr 22.
•   Damewood MD, Shen W, Zacur HA, Schlaff WD, Rock JA, Wallach EE
  Disappearance of exogenously administered human chorionic gonadotropin. Fertil Steril. 1989 Sep;52(3):398-400.
•   Elefant E, Biour B, Blumberg-Tick J, Roux C, Thomas F
  Administration of a gonadotropin-releasing hormone agonist during pregnancy: follow-up of 28 pregnancies exposed to triptoreline. Fertil Steril. 1995 May;63(5):1111-3.
•   Gartner B, Moreno C, Marinaro A, Remohí J, Simón C, Pellicer A
  Accidental exposure to daily long-acting gonadotrophin-releasing hormone analogue administration and pregnancy in an in-vitro fertilization cycle. Hum Reprod. 1997 Nov;12(11):2557-9.
•   Golan A, Ron-el R, Herman A, Weinraub Z, Soffer Y, Caspi E
  Fetal outcome following inadvertant administration of long-acting DTRP6 GnRH microcapsules during pregnancy: a case report. Hum Reprod. 1990 Jan;5(1):123-4.
•   Gómez R, Soares SR, Busso C, Garcia-Velasco JA, Simón C, Pellicer A
  Physiology and pathology of ovarian hyperstimulation syndrome. Semin Reprod Med. 2010 Nov;28(6):448-57. doi: 10.1055/s-0030-1265670. Epub 2010 Nov 16. Review.
•   Isherwood PJ, Ibrahim ZH, Matson PL, Morroll DR, Burslem RW, Lieberman BA
  Endocrine changes in women conceiving during treatment with an LHRH agonist. Hum Reprod. 1990 May;5(4):409-12.
•   Jackson AE, Curtis P, Amso N, Shaw RW
  Exposure to LHRH agonists in early pregnancy following the commencement of mid-luteal buserelin for IVF stimulation. Hum Reprod. 1992 Oct;7(9):1222-4.
•   Leth-Moller K, Hammer Jagd S, Humaidan P
  The Luteal Phase after GnRHa Trigger-Understanding An Enigma. Int J Fertil Steril. 2014 Oct;8(3):227-34. Epub 2014 Nov 1. Review.
•   Pirard C, Loumaye E, Laurent P, Wyns C
  Contribution to More Patient-Friendly ART Treatment: Efficacy of Continuous Low-Dose GnRH Agonist as the Only Luteal Support-Results of a Prospective, Randomized, Comparative Study. Int J Endocrinol. 2015;2015:727569. doi: 10.1155/2015/727569. Epub 2015 Apr 5.
•   Tesarik J, Hazout A, Mendoza C
  Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Hum Reprod. 2004 May;19(5):1176-80. Epub 2004 Apr 7.
•   Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N, Mendoza C
  Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod. 2006 Oct;21(10):2572-9. Epub 2006 Aug 22.
•   van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M
  Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015 Jul 7;(7):CD009154. doi: 10.1002/14651858.CD009154.pub3. Review.
•   Weissman A, Shoham Z
  Favourable pregnancy outcome after administration of a long-acting gonadotrophin-releasing hormone agonist in the mid-luteal phase. Hum Reprod. 1993 Mar;8(3):496-7.
•   Wilshire GB, Emmi AM, Gagliardi CC, Weiss G
  Gonadotropin-releasing hormone agonist administration in early human pregnancy is associated with normal outcomes. Fertil Steril. 1993 Dec;60(6):980-3.
•   Young DC, Snabes MC, Poindexter AN 3rd
  GnRH agonist exposure during the first trimester of pregnancy. Obstet Gynecol. 1993 Apr;81(4):587-9.
•   Youssef MA, Van der Veen F, Al-Inany HG, Mochtar MH, Griesinger G, Nagi Mohesen M, Aboulfoutouh I, van Wely M
  Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev. 2014 Oct 31;(10):CD008046. doi: 10.1002/14651858.CD008046.pub4. Review.

Luteal Phase Support Using Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone Supplementation in High Responders Following GnRHa Triggering - A Prospective Randomized Controlled Trial

Details for clinical trial NCT04797338